Article
Efforts to Derail 340B Contract Pharmacy Protections Hit New Low
By Ted Slafsky Last year, I wrote a column about the irresponsible tactics of a Washington D.C.-based dark money group that poured millions of dollars into
Article
Momentum Continues in States on Contract Pharmacy Access
In last month’s column, I wrote about a reprehensible campaign by 340B opponents to tie this critically important drug discount program to the contentious
Article
340B and The Likely Path Forward
After 340B Hearing and New Bills Emerging; The Likely Path Forward Despite its importance, the 340B drug discount program rarely ever goes under the
Article
Three Key Observations from Efforts to Restore 340B Discounts in the States
After six months of heated battles in the states to restore access to 340B drug discounts in the contract pharmacy setting, it’s a good time to reflect on
Article
Turning 340B Into a Rebate Program a Non-Starter
If things were not difficult enough already for 340B providers, hospitals woke up on Friday morning to an announcement that one of the world’s biggest drug
Article
CMS Should Heed the Advice of 340B Community on Medicare Negotiations
The Biden administration deserves credit for playing a key role in passing the first law in history to allow the government to negotiate lower drug prices for
Article
Much-Needed Wins for 340B Providers but Challenges Could Be Lurking
After a long period in which many 340B providers felt helpless, the last month has brought two major wins. First, in a key decision on Sept. 30, a federal
Article
Verity Solutions Recognized #1 in KLAS 2024 Emerging Solutions Top 20 Report
Verity Solutions’ VERISAVE® was recognized in the 2024 KLAS Emerging Solutions Top 20 Report. The top 20 emerging solutions were selected by healthcare
Article
Six U.S. House Members for 340B Stakeholders to Watch in 2025
There are 435 members of the U.S. House and 100 U.S. Senators, and each one of them can influence the 340B drug discount program. But it is the lawmakers
Article
In the Senate, Keep an Eye on Two Powerful Lawmakers with Very Different Views on 340B
As I mentioned in my last column, the 119th Congress includes hundreds of members of the U.S. House of Representatives and 100 U.S. Senators, but
Article
Post Election Analysis: Implications for the 340B Program
With President-elect Donald Trump’s (R) big victory and the GOP takeover of the U.S. Senate in Tuesday’s elections, we are likely to see increased scrutiny
Article
States Progress on Contract Pharmacy Protection Legislation
Despite 340B Opponents’ Unprecedented Tactics, Many States Progress on Contract Pharmacy Protection Legislation After over 30 years of working in Washington,
Article
Key Takeaways from the SUSTAIN 340B Act and Things to Consider When Weighing In (Part 2)
(Part Two of a Two-Part Analysis) In February, the U.S. Senate bipartisan “Group of Six” released an eagerly anticipated discussion draft bill and
Article
Key Takeaways from Senate Group of Six Draft 340B Bill (Part 1)
(Part One of a Two-Part Analysis) After reviewing comments from over 250 stakeholders, meeting with various interest groups and holding regular staff meetings,
Article
Action on 340B Contract Pharmacies Turns to the States
As we approach the 16-month mark since we had pivotal arguments over the 340B contract pharmacy program in two federal appellate courts and Congress continues